KR101673889B1 - Ｆⅷ-유래 펩타이드 - Google Patents

Ｆⅷ-유래 펩타이드 Download PDF

Info

Publication number
KR101673889B1
KR101673889B1 KR1020117028276A KR20117028276A KR101673889B1 KR 101673889 B1 KR101673889 B1 KR 101673889B1 KR 1020117028276 A KR1020117028276 A KR 1020117028276A KR 20117028276 A KR20117028276 A KR 20117028276A KR 101673889 B1 KR101673889 B1 KR 101673889B1
Authority
KR
South Korea
Prior art keywords
ser
leu
ile
thr
arg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020117028276A
Other languages
English (en)
Korean (ko)
Other versions
KR20120023023A (ko
Inventor
데이비드 레이트
Original Assignee
아피토프 인터내셔날 엔브이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40834163&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101673889(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 아피토프 인터내셔날 엔브이 filed Critical 아피토프 인터내셔날 엔브이
Publication of KR20120023023A publication Critical patent/KR20120023023A/ko
Application granted granted Critical
Publication of KR101673889B1 publication Critical patent/KR101673889B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020117028276A 2009-05-18 2010-05-17 Ｆⅷ-유래 펩타이드 Expired - Fee Related KR101673889B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0908515.0A GB0908515D0 (en) 2009-05-18 2009-05-18 Peptide
GB0908515.0 2009-05-18
PCT/GB2010/000997 WO2010133834A2 (en) 2009-05-18 2010-05-17 Peptide

Publications (2)

Publication Number Publication Date
KR20120023023A KR20120023023A (ko) 2012-03-12
KR101673889B1 true KR101673889B1 (ko) 2016-11-08

Family

ID=40834163

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020117028276A Expired - Fee Related KR101673889B1 (ko) 2009-05-18 2010-05-17 Ｆⅷ-유래 펩타이드

Country Status (30)

Country Link
US (1) US8703705B2 (enExample)
EP (2) EP2465523B1 (enExample)
JP (1) JP5784009B2 (enExample)
KR (1) KR101673889B1 (enExample)
CN (1) CN102458445B (enExample)
AU (1) AU2010250957B2 (enExample)
BR (1) BRPI1012845A2 (enExample)
CA (1) CA2762020C (enExample)
CL (1) CL2011002893A1 (enExample)
CO (1) CO6460780A2 (enExample)
CY (1) CY1115832T1 (enExample)
DK (1) DK2465523T3 (enExample)
EA (1) EA027229B1 (enExample)
EC (1) ECSP11011540A (enExample)
ES (1) ES2525448T3 (enExample)
GB (1) GB0908515D0 (enExample)
HR (1) HRP20141182T1 (enExample)
IL (1) IL216199A (enExample)
MX (1) MX2011012270A (enExample)
MY (1) MY168207A (enExample)
NZ (2) NZ613713A (enExample)
PL (1) PL2465523T3 (enExample)
PT (1) PT2465523E (enExample)
RS (1) RS53671B1 (enExample)
SG (2) SG190573A1 (enExample)
SI (1) SI2465523T1 (enExample)
SM (1) SMT201400186B (enExample)
UA (1) UA110921C2 (enExample)
WO (1) WO2010133834A2 (enExample)
ZA (1) ZA201108446B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX353233B (es) 2009-12-06 2018-01-08 Bioverativ Therapeutics Inc Polipéptidos híbridos y quiméricos del factor viii-fc, y métodos de uso de los mismos.
PL2917232T3 (pl) * 2012-11-12 2017-09-29 Apitope International Nv Pochodzące od czynnika VIII peptydy do zastosowania w leczeniu hemofilii A
GB201314052D0 (en) * 2013-08-06 2013-09-18 Apitope Int Nv Peptides
PE20231949A1 (es) 2015-10-30 2023-12-05 Spark Therapeutics Inc VARIANTES DEL FACTOR VIII REDUCIDO CON CpG, COMPOSICIONES Y METODOS Y USOS PARA EL TRATAMIENTO DE TRASTORNOS DE LA HEMOSTASIA
WO2018102743A1 (en) 2016-12-02 2018-06-07 Bioverativ Therapeutics Inc. Methods of treating hemophilic arthropathy using chimeric clotting factors
RS66972B1 (sr) 2018-05-18 2025-07-31 Bioverativ Therapeutics Inc Metode lečenja hemofilije a

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005538694A (ja) * 2002-04-18 2005-12-22 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 修飾されたｖｉｉｉ因子

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1311542T1 (sl) 2000-08-21 2009-02-28 Apitope Technology Bristol Ltd Tolerogenski peptidi
US20040096456A1 (en) * 2000-12-01 2004-05-20 Conti-Fine Bianca M Method to treat hemophilia
AU2002312660A1 (en) * 2001-05-31 2002-12-16 D. Collen Research Foundation Vzw Onderwijsen Navorsing Campus Gasthuisberg K.U. Leuven Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools
WO2002096454A1 (en) 2001-05-31 2002-12-05 D. Collen Research Foundation Vzw Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools
GB0723712D0 (en) * 2007-12-04 2008-01-16 Apitope Technology Bristol Ltd Peptides
GB0801513D0 (en) * 2008-01-28 2008-03-05 Circassia Ltd Peptides from factor VIII

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005538694A (ja) * 2002-04-18 2005-12-22 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 修飾されたｖｉｉｉ因子

Also Published As

Publication number Publication date
SMT201400186B (it) 2015-01-15
GB0908515D0 (en) 2009-06-24
CA2762020A1 (en) 2010-11-25
CA2762020C (en) 2018-08-28
CN102458445B (zh) 2014-06-11
SI2465523T1 (sl) 2015-02-27
IL216199A0 (en) 2012-01-31
MX2011012270A (es) 2011-12-12
KR20120023023A (ko) 2012-03-12
WO2010133834A3 (en) 2011-02-24
WO2010133834A2 (en) 2010-11-25
US20120121625A1 (en) 2012-05-17
EP2465523B1 (en) 2014-10-01
CL2011002893A1 (es) 2012-08-17
JP5784009B2 (ja) 2015-09-24
HK1173358A1 (en) 2013-05-16
SG176138A1 (en) 2011-12-29
EP2432494A2 (en) 2012-03-28
JP2012527440A (ja) 2012-11-08
HRP20141182T1 (hr) 2015-02-13
DK2465523T3 (en) 2014-12-15
NZ613713A (en) 2014-10-31
PT2465523E (pt) 2014-12-09
SG190573A1 (en) 2013-06-28
US8703705B2 (en) 2014-04-22
NZ596300A (en) 2013-08-30
UA110921C2 (uk) 2016-03-10
EA201171430A1 (ru) 2012-05-30
BRPI1012845A2 (pt) 2016-10-11
CO6460780A2 (es) 2012-06-15
AU2010250957A1 (en) 2011-12-01
EP2465523A1 (en) 2012-06-20
RS53671B1 (sr) 2015-04-30
ECSP11011540A (es) 2012-01-31
AU2010250957B2 (en) 2015-01-15
ES2525448T3 (es) 2014-12-23
IL216199A (en) 2015-11-30
EA027229B1 (ru) 2017-07-31
PL2465523T3 (pl) 2015-03-31
CY1115832T1 (el) 2017-01-25
ZA201108446B (en) 2013-01-30
CN102458445A (zh) 2012-05-16
MY168207A (en) 2018-10-15

Similar Documents

Publication Publication Date Title
KR101519840B1 (ko) Ｆⅷ 펩타이드 및 혈우병 환자 내성화시 그의 용도
KR101673889B1 (ko) Ｆⅷ-유래 펩타이드
KR102165486B1 (ko) 펩타이드
AU2014200237B2 (en) FVIII peptides and their use in tolerising haemophiliacs
HK1172240B (en) Fviii-derived peptides and their use in tolerising haemophiliacs
HK1172240A (en) Fviii-derived peptides and their use in tolerising haemophiliacs
HK1173358B (en) Fviii-derived peptides
HK1144292B (en) Fviii peptides and their use in tolerising haemophiliacs

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20191103

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20191103